29.29

2.88% -0.8794

Kymera Therapeutics Inc (KYMR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$30.17

Aprire:

$29.5

Volume 24 ore:

200.73K

Relative Volume:

0.28

Capitalizzazione di mercato:

$1.91B

Reddito:

$87.56M

Utile/perdita netta:

$-167.47M

Rapporto P/E:

-12.52

EPS:

-2.34

Flusso di cassa netto:

$-148.20M

1 W Prestazione:

-3.14%

1M Prestazione:

-4.56%

6M Prestazione:

-34.86%

1 anno Prestazione:

-14.43%

Intervallo 1D:

$29.15

$29.79

Intervallo di 1 settimana:

$29.15

$31.47

Portata 52W:

$19.45

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Nome

Kymera Therapeutics Inc

Settore

Healthcare (1178)

Industria

Biotechnology (668)

Telefono

857-285-5314

Indirizzo

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Dipendente

208

Cinguettio

Prossima data di guadagno

2025-02-21

Ultimi documenti SEC

KYMR's Discussions on Twitter

Confronta KYMR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KYMR Kymera Therapeutics Inc	29.30	1.95B	87.56M	-167.47M	-148.20M	-2.34
ONC Beigene Ltd Adr	240.75	24.41B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.21	111.55B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.335	42.47M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	589.97	63.16B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.17	5.92B	0	-153.72M	-103.81M	-2.00

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-13	Iniziato	Citigroup	Buy
2024-12-10	Iniziato	BTIG Research	Buy
2024-12-06	Iniziato	BMO Capital Markets	Market Perform
2024-12-02	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-11-18	Iniziato	Stephens	Overweight
2024-09-09	Ripresa	Leerink Partners	Outperform
2024-08-26	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2024-04-22	Iniziato	Oppenheimer	Outperform
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2024-01-04	Aggiornamento	JP Morgan	Neutral → Overweight
2024-01-03	Downgrade	BofA Securities	Buy → Neutral
2023-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-06-30	Iniziato	Truist	Buy
2023-05-05	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-12-06	Downgrade	Credit Suisse	Outperform → Neutral
2022-11-08	Iniziato	Raymond James	Mkt Perform
2022-08-15	Iniziato	Jefferies	Buy
2022-08-03	Iniziato	Goldman	Buy
2022-07-20	Iniziato	SVB Leerink	Mkt Perform
2022-04-28	Iniziato	Credit Suisse	Outperform
2022-03-10	Iniziato	JP Morgan	Neutral
2022-02-10	Iniziato	Wells Fargo	Overweight
2021-09-30	Iniziato	B. Riley Securities	Neutral
2021-09-30	Iniziato	Stifel	Buy
2021-09-10	Downgrade	BofA Securities	Buy → Neutral
2021-05-21	Iniziato	UBS	Buy
2021-04-14	Iniziato	Berenberg	Buy
2020-12-04	Iniziato	H.C. Wainwright	Buy
2020-09-15	Iniziato	BofA Securities	Neutral
2020-09-15	Iniziato	Cowen	Outperform
2020-09-15	Iniziato	Guggenheim	Buy
2020-09-15	Iniziato	Morgan Stanley	Equal-Weight

Mostra tutto

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025

May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus

May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com

May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria

May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus

May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025

May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025

May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025

May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025